Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Neurology

medtech-news-for-ecential-robotics-microvention-ge-healthcare

Notizia - Recent Pharma, Healthcare and Biotech Happenings

STRATA Skin Sciences’ XTRAC Momentum™ 1.0 Device Approved in Japan; eCential Robotics Received FDA 510(k) Clearance for Spine Navigation and Robotic-Assistance Device; MicroVention Announced the Results of the Clinical Evaluation of WEB™ 17 Device; Neuspera Medical, Inc.’s SANS-UUI Pivotal Clinical Trial; GE HealthCare Announced an Agreement to Acquire the Clinical Artificial Intelligence Business; Sutter Health Implemented World’s First Wearable Doppler Ultrasound Patch

Explore More...
soticlestat-for-epilepsy

Soticlestat (TAK-935): A Paradigm Shift in Epilepsy Treatment Strategies

xcopri-phase-i-trial

Improving Epilepsy Care: XCOPRI’s Effectiveness and Safety

fosgonimeton-for-alzheimers-disease

The Silent Victory: Athira Pharma’s Quest Against Alzheimer’s

semaglutide-phase-iii-pioneer-sustain-and-step-trial

Semaglutide: Unveiling Hope for Alzheimer’s Disease Patients

prx012-and-prx123-for-alzheimers-disease

Prothena’s Promise: Revolutionizing Alzheimer’s Treatment with a Breakthrough Therapy

donanemab-phase-iii-trailblazer-alz-2-trial

Brighter Tomorrows: Donanemab’s Role in Elevating Patient and Clinician Outcomes

pharma-news-for-ipsen-synox-roche-abbvie

Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation

ipx203-phase-iii-clinical-study

Unveiling the Safety and Dosing Patterns of IPX203: Insights from a Phase III Clinical Study

frexalimab-phase-ii-trial

A New Dawn: Frexalimab’s Quest to Redefine Multiple Sclerosis Therapy

axs-07-phase-iii-momentum-and-intercept-trial

AXS-07 Shines at AAN 2024: A New Era in Migraine Treatment

ub-312-phase-i-trial

Target Engagement of UB-312 in Parkinson’s Disease Patients: Insights from CSF Analysis

ozanimod-enlighten-trial-result

Charting Progress: Ozanimod’s Influence on Brain Dynamics in RMS

neuroderms-nd0612-for-parkinsons-disease

Breakthroughs in Parkinson’s Management: Key Findings from Neuroderm’s ND0612 Studies

soliris-and-ultomiris-for-gmg-management

Enhancing Patient Care: Transitioning from Eculizumab to Ravulizumab in gMG Management

efgartigimod-for-gmg-treatment

Revolutionizing gMG Treatment: Efgartigimod’s Triumph in Curtailing Oral Corticosteroid Dependence

p2b001-phase-ii-and-phase-iii-results

Advancing Parkinson’s Disease Treatment: P2B001 Offers Promising Safety Profile in Early PD Patients

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader